Navigation Links
Synvista Therapeutics Highlights New Data Demonstrating the Clinical Benefit of Vitamin E Therapy in Patients Identified on the Basis of Haptoglobin Phenotype Testing
Date:11/5/2007

tudy, more than 3,000 patients were tested for Haptoglobin phenotype, and 984 of these who had the Hp2-2 phenotype were randomized to receive either natural source Vitamin E (400 IU daily) or placebo. Primary endpoints of the study were non-fatal myocardial infarction (MI--heart attack), stroke and cardiovascular death. Results demonstrated a greater than 50% decrease in cardiovascular events in patients receiving Vitamin E (1.0 percent compared to 3.8 percent, p=0.004), leading to early termination of the study. Investigators determined this result to be predominantly due to a significant decrease in non-fatal myocardial infarction in the Vitamin E group.

"Our research group has postulated that the profoundly increased risk of, MI, stroke and cardiovascular death observed in DM patients with Hp2-2, established in many observational studies of more than 20,000 patients in recent years, may be a consequence of a defect in the antioxidant protection of Hp2-2," added Dr. Levy. "As a member of my group, Dr. Rabea Asleh, reported earlier today, this defect may interfere with reverse cholesterol transport. This in turn may promote a more inflamed and labile atherosclerotic plaque. It is gratifying to have had this opportunity to collaborate with Clalit Health Services, the largest health plan in Israel, in a large prospective clinical trial that provides strong support for the claim that Vitamin E can be targeted to DM patients with Hp2-2 and provide a significant clinical benefit."

About Synvista Therapeutics

Synvista Therapeutics is a biopharmaceutical company developing small molecule drugs to treat and prevent cardiovascular disease and to treat nephropathy in people with diabetes. The Company has identified several product candidates that it believes represent novel approaches to some of the largest pharmaceutical markets. The Company's portfolio includes orally bioavailable, organoselenium mimics of glutathione peroxidase. These compounds metaboliz
'/>"/>

SOURCE Synvista Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Synvista Therapeutics Alagebrium Shows Potential for use in Treating Diabetes-Related Gastrointestinal Complications
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
4. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
7. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
8. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
11. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX ), ... commercialization of innovative therapies for the treatment of acute ... officer Howie Rosen will be presenting at ... Tim Morris will be presenting at JMP Securities ... as follows: Jefferies 2015 Healthcare Conference Date: ...
(Date:5/21/2015)... Research and Markets ( ... "Market Assessment of Respiratory Diagnostics in the ... offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,This research service ... market in the United States ... service provides detailed analysis of the current and ...
(Date:5/21/2015)... WASHINGTON , May 21, 2015 ... following statement regarding the Medicare Part D offsets ... Century Cures initiative: "If the 21st Century ... billions from America,s premier health program – Medicare ... it may yield down the road. ...
Breaking Medicine Technology:AcelRx Pharmaceuticals to Present at Two Upcoming Investor Conferences In June 2United States and Europe Respiratory Diagnostics Market Assessment 2015 2
... France, Oct. 8 Vical Incorporated (Nasdaq: ... new nonclinical data,demonstrating that the company,s Vaxfectin(R) adjuvant ... disease vaccines and,peptide-based cancer vaccines. Alain P. Rolland, ... will present the data today,Wednesday, October 8, at ...
... 7 Prometheus Laboratories Inc., a,specialty pharmaceutical ... PROMETHEUS(R) IBS Diagnostic, the first and only ... findings suggest measurable,differences in the expression of ... non-IBS patients. The identification of these biomarkers,combined ...
Cached Medicine Technology:Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 2Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 3Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 4Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 5Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting 2Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting 3
(Date:5/24/2015)... 2015 ProPin is a set of ... X. Utilize ProPin to pin point locations on a map, ... , ProPin allows users to choose from 30 simplistic presets ... With on-screen controls, video editors can easily manipulate ProPin presets as ... mark with absolute ease. , Using ProPin is easy, simply drag ...
(Date:5/24/2015)... WI (PRWEB) May 24, 2015 ... Health System CEO - The ... and honored at the fourth annual ... April 15 at Geneva National in ... school): ,     -Badger High School,         Jonathan ...
(Date:5/23/2015)... On May 13, Nithyananda Yoga Foundation organized a ... learned through meditation and initiation at Special Holistic School ... Yogamaatha, a nine-year-old girl from North Carolina, stunned an ... the 2015 Business Advocacy Summit at Capitol Hill in ... In a demonstration that lasted three hours, Yogamaatha was ...
(Date:5/23/2015)... 2015 On Wednesday, May 20, 2015, ... has been the target of a sophisticated cyberattack,” and ... company’s ongoing Information Technology (IT) security efforts in the ... The most notable attack on health insurers was reported ... nation’s second largest health insurer, revealed that they had ...
(Date:5/23/2015)... A live auction will be held to sell over 5,200 ... medical facilities around the United States. Various types of ... exam and much more. , The live auction will ... at 9:00am CDT each day. The equipment is at their ... IL 60160. Anyone can participate in the auction including ...
Breaking Medicine News(10 mins):Health News:Developers at Pixel Film Studios Release ProPin for Final Cut Pro X. 2Health News:Mercy Foundation Honors 16 Students for Making a Difference - Mercy Health System Javon Bea 2Health News:Nine-Year-Old Reads Blindfolded at Business Advocacy Summit 2Health News:Nine-Year-Old Reads Blindfolded at Business Advocacy Summit 3Health News:One Headline Making Cyber Attack Sparks Discovery of Another 2Health News:One Headline Making Cyber Attack Sparks Discovery of Another 3Health News:One Headline Making Cyber Attack Sparks Discovery of Another 4Health News:Over 5,200 Lots of Medical Equipment Will Be Sold by Live Auction 2
... for Childhood Cancer Research (NCCCR), a newly established division of Nemours ... in Wilmington, DE, has secured $1,020,000 in external funding for awards ... ... January 8, 2009-- The research team at the Nemours Center ...
... may reduce risk of cardiovascular disease , , THURSDAY, Jan. ... the millions of American men and women with type ... the day may be symptoms of obstructive sleep apnea, ... diabetics. , Based on strong preliminary evidence linking the ...
... Minnesota receives $20,000 to support local programs as part ... Special Olympics Minnesota recently received $20,000 ... Special Olympics International,s new national program. Project UNIFY is ... States in an effort to promote school communities where ...
... While the U.S. Food and Drug Administration Drug has quickened ... diseases for which new therapeutics are being developed has resulted ... for the Study of Drug Development. , The average time ... years in the 2005-07 period, but longer average clinical phase ...
... Limited (Nasdaq: WCRX ) announced today that ... Conference on Tuesday, January 13, 2009 at 3:00 p.m. ... Boissonneault, President and Chief Executive Officer and Paul Herendeen, ... will be webcast live for all interested parties at ...
... today announced that the second annual Health IT ... content partnership with Health Industry Insights, an IDC company, ... in Phoenix, Arizona from April 29-May 1, 2009. Originally ... moving to the four-diamond Phoenix resort in order to ...
Cached Medicine News:Health News:Nemours Center for Childhood Cancer Research Receives Over $1 Million in Grants for Cancer Research in 2008 2Health News:Nemours Center for Childhood Cancer Research Receives Over $1 Million in Grants for Cancer Research in 2008 3Health News:Nemours Center for Childhood Cancer Research Receives Over $1 Million in Grants for Cancer Research in 2008 4Health News:Doctors Urged to Screen Diabetics for Sleep Apnea 2Health News:Doctors Urged to Screen Diabetics for Sleep Apnea 3Health News:Special Olympics Minnesota Launches Project UNIFY to Energize Youth 2Health News:New drug development still takes 8 years despite faster FDA review, according to Tufts CSDD 2Health News:CrossTech Forums Announces Health IT Insight 2009 Moving to Arizona Grand Resort in Phoenix; Executive Summit to Take Place April 29-May 1 2Health News:CrossTech Forums Announces Health IT Insight 2009 Moving to Arizona Grand Resort in Phoenix; Executive Summit to Take Place April 29-May 1 3
A simple, in-office test for the detection of mononucleosis. Easy to use with fast, accurate results within minutes....
... The Wampole PreVue B. Burgdorferi Antibody ... membrane assay for the qualitative presumptive (first ... to B. burgdorferi in human serum or ... use and relative accuracy make the Wampole ...
Comprehensive range of integrated implants and instruments including - Basic, Small, Mini, Pelvic and Foot Sets....
Comprehensive range of integrated implants and instruments including - Basic, Small, Mini, Pelvic and Foot Sets....
Medicine Products: